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Key points: 
• Natural estrogens modulate human hematopoietic stem and progenitor cells. 
• E2 and E4 increase human hematopoietic reconstitution in NSG mice. 
 
Abstract: 
Hematopoietic Stem and Progenitor Cells are crucial in the maintenance of lifelong 
production of all blood cells. These Stem Cells are highly regulated to maintain 
homeostasis through a delicate balance between quiescence, self-renewal and 
differentiation. However, this balance is altered during the hematopoietic recovery after 
Hematopoietic Stem and Progenitor Cell Transplantation. Transplantation efficacy can be 
limited by inadequate Hematopoietic Stem Cells number, poor homing, low level of 
engraftment, or limited self-renewal.  
As recent evidences indicate that estrogens are involved in regulating the hematopoiesis, 
we sought to examine whether natural estrogens (estrone or E1, estradiol or E2, estriol or 
E3 and estetrol or E4) modulate human Hematopoietic Stem and Progenitor Cells. Our 
results show that human Hematopoietic Stem and Progenitor Cell subsets express 
estrogen receptors, and whose signaling is activated by E2 and E4 on these cells. 
Additionally, these natural estrogens cause different effects on human Progenitors in 
vitro. We found that both E2 and E4 expand human Hematopoietic Stem and Progenitor 
Cells. However, E4 was the best tolerated estrogen and promoted cell cycle of human 
Hematopoietic Progenitors. Furthermore, we identified that E2 and, more significantly, E4 
doubled human hematopoietic engraftment in immunodeficient mice without altering 
other Hematopoietic Stem and Progenitor Cells properties. Finally, the impact of E4 on 
promoting human hematopoietic engraftment in immunodeficient mice might be 
mediated through the regulation of mesenchymal stromal cells in the bone marrow niche. 
Together, our data demonstrate that E4 is well tolerated and enhances human 
reconstitution in immunodeficient mice, directly by modulating human Hematopoietic 
Progenitor properties and indirectly by interacting with the bone marrow niche. This 
application might have particular relevance to ameliorate the hematopoietic recovery 
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after myeloablative conditioning, especially when limiting numbers of Hematopoietic 
Stem and Progenitor Cells are available. 
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Introduction 
 
Hematopoietic Stem Cells (HSCs) are a rare cell population resident in the bone marrow of 
adult mammals and sit atop a hierarchy of progenitors that become progressively 
restricted to several or a single blood lineage. HSCs are capable of self-renewal and 
multipotent differentiation to all blood cell lineages
1
, becoming crucial for the 
maintenance of lifelong production of all blood cells. They are homeostatically regulated 
through a delicate balance between quiescence, self-renewal and differentiation. 
Although HSCs divide infrequently, they are activated to proliferate in response to bone 
marrow injury to re-establish homeostasis
2
. On the other hand, Hematopoietic Stem and 
Progenitor Cell Transplantation (HSPCT) is routinely used to reconstitute hematopoiesis 
after myeloablation, as a result of leukemia or hematopoietic genetic disease treatments. 
However, HSPCT efficacy can be limited by inadequate number, poor homing, low 
engraftment, or differentiation stress of Hematopoietic Stem and Progenitor Cells (HSPCs). 
Different approaches have been attempted to solve these problems, such as using 
different sources of HSPCs
3-5
, ex vivo expansion of HSPCs
6-10
 or stimulating them by using 
accessory molecules
11, 12
 or cells
13
. However, these approaches require extensive 
knowledge regarding HSPC regulation and how their properties can be boosted to 
maximize their efficacy to reconstitute the patient’s blood system after HSPCT
1, 14
. 
 
Estrogen is the primary female sex hormone and, apart from its known role in the 
reproductive system, it is responsible for controlling many cellular and molecular 
processes including growth and differentiation. Estrogens act through genomic or nuclear 
signaling and non-genomic or membrane-initiated steroid signaling (MISS), modulating 
intracellular second messengers
15
. The four major naturally-occurring estrogens in women 
are estrone (E1), estradiol (E2), estriol (E3) and estetrol (E4). E1 is the predominant 
estrogen in postmenopausal women. E2 is considered the active estrogen during the 
estrous cycle. E3 and E4 are synthesized during pregnancy by the placenta and fetal liver 
respectively, but their physiological roles are essentially unknown
16
.  
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Recent evidence indicates that E2 is involved in regulating the proliferation and lineage 
commitment of HSCs
17
. But the studies are few and sometimes their results are 
contradictory. But despite E2 treatment was able to specifically increase the number of 
vascular HSCs, long term repopulating capacity of those HSCs was limited
18
. Additionally, 
this estrogen was shown to promote the cell cycle of HSCs and multipotent progenitors 
(MPP) and increase erythroid differentiation in females
19
, also during pregnancy
19
. 
Furthermore, E2 favors hematopoietic regeneration through the activation of the 
telomerase activity
20-22
 or the stimulation of the unfolded protein response (UPR) on 
mouse HSCs, which sustain protein homeostasis to favor hematopoietic regeneration
23
. 
On the contrary, tamoxifen, whose active metabolite (4-hydroxytamoxifen) acts as an 
estrogen receptor antagonist, reduces the number of MPPs and short-term HSCs but 
activates the proliferation of long-term HSCs
24
. In addition, E2 might modulate HSCs 
indirectly through activating bone marrow mesenchymal stromal cells (BM-MSCs). E2 
treatment has been described to activate MSC osteogenic differentiation and also 
promotes the secretion of GM-CSF and IL6, which improved the number of HSCs by 
modulating their niche
25
. Therefore, the estrogen-mediated regulation of HSPCs can also 
occur indirectly to change the HSC bone marrow niche. For that reason, fully 
understanding the role of estrogens in HSC regulation is essential for being able to further 
develop the clinical potential of these hormones. 
 
In this work, we have examined the impact of natural estrogens on human HSPCs. E2 and 
E4 treatment ex vivo expanded human HSPCs, and more importantly, the administration 
of E4 to immunodeficient mice previously transplanted with human HSPCs enhanced the 
engraftment level of human hematopoietic cells. 
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Methods 
 
Human Cord Blood-CD34
+
samples and Bone Marrow Mesenchymal Stromal Cells 
Umbilical cord blood samples (CB) from healthy donors were provided by “Centro de 
Transfusión de la Comunidad de Madrid”. All samples were collected under written 
consent and Centro de Transfusión de la Comunidad de Madrid‘s institutional review 
board agreement (number PKDEFIN [SAF2017-84248-P]). Mononuclear cells were 
obtained by fractionation in Ficoll-hypaque according to manufacturer’s 
recommendations (GE Healthcare). Purified CB-CD34
+
 cells were obtained using a MACS 
CD34 Micro-Bead kit (Miltenyi Biotec). Cells were viably frozen in 10% dimethyl sulfoxide 
solution and stored at liquid nitrogen until their use. 
 
Mononuclear cells from human Bone Marrow (BM) were obtained by Ficoll-Paque Plus 
density gradient from heparinized BM samples obtained from healthy donors after 
informed consent. All the procedures were in accordance with the Helsinki Declaration of 
1975, revised in 2000. Samples were then cultured at 1.6×10
5
cells/cm
2 
in MesenCult 
medium plus supplements for human cells (Stemcell Technologies). After 24h, non-
adherent cells were discarded. Fresh medium was added and replaced twice a week. At 
80% confluence, adherent cells were trypsinized, washed, and seeded at 4×10
3
cells/cm
2
. 
In all the experiments, BM-MSCs were used at 5–8 passages. 
 
Hematopoietic transplant protocol in immunodeficient mice 
All the mice were kept under standard pathogen-free conditions in the animal facility of 
CIEMAT. All animal experiments were performed in compliance with European and 
Spanish legislations and institutional guidelines. The protocol was approved by “Consejeria 
de Medio Ambiente y Ordenación del Territorio” (Protocol number PROEX 078/15).  
 
CB-CD34
+
 cells were administered through tail vein of female or male NOD.Cg-
Prkdc
scid
 Il2rg
tm1Wjl
/SzJ (NSG) mice sub-lethally irradiated the day before transplant with 
1.5Gy. Three days later, the animals were treated with vehicle (olive oil) or with daily 
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doses of either E2 or E4 (2μg of estrogen per day) intraperitoneally for four days. Four 
months post transplantation (mpt), mice were sacrificed and BM from long bones of these 
animals was collected. Additionally, when hematopoietic niche analysis was involved, the 
long bones were flushed, cut in small pieces and crushed before being digested with 
200U/mL Collagenase IV / 2μg/mL DNaseI in HBSS at 37°C for 45 minutes. The human 
engraftment was analyzed by flow cytometry (LSR Fortessa; BD). The cells were stained 
with hCD45-APCCy7 and hCD3-APC (BioLegend), hCD45-FITC, hCD33-PE, hCD19-FITC and 
hCD235a-FITC (Beckman Coulter), hCD34-Pecy5 (Immunotech), hCD38-PE, hCD90-APC, 
mCD45.1-PE, mCD45.1-Biotin and Ter119-Biotin (BD), mCD140a-APC (Pdgfra-APC, 
eBiosience) and mCD144-PE (VE-Cadherin-PE, eBiosience). DAPI-positive cells were 
excluded from the analysis. Analysis was performed using FlowJo software. 
 
Additionally, hCD45
+
 population from primary mice was sorted in an Influx Cell Sorter 
(BD), and 1x10
6
 hCD45
+
 cells were transplanted into sub-lethally irradiated female 
secondary NSG recipients. 4mpt, the animals were sacrificed and analyzed as previously 
described.  
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Results 
 
Engraftment of human CB-CD34
+
 is favored in female immunodeficient mice 
It has been previously described that the engraftment of highly purified human HSCs (Lin
-
CD34
+
CD38
-
CD90
+
CD45RA
-
) is improved when these cells are transplanted into 
immunodeficient female recipients, as compared to male recipients
26
. To investigate if this 
enhanced engrafting potential in female recipients was also present in CB-CD34
+
 cells, we 
transplanted different amounts of HSPCs into sub-lethally irradiated animals. As occurred 
when highly purified HSCs were transplanted, we observed higher engraftment of human 
HSPCs in female NSG animals than in their male counterparts (Figure 1A). Human 
engraftment in mouse bone marrow (BM) 4mpt was 61.06±26.07% (mean±SD) in female 
mice and 18.94±13.93% in male mice when 5x10
4
 CB-CD34
+
 cells had been transplanted. 
Interestingly, this impairment in the engrafting potential was even higher when only 5x10
3
 
CB-CD34
+
 cells were transplanted (38.74±30.42% BM cells were of human origin in female 
animals versus only 0.19±0.27% in male animals) (Figure 1B). Therefore, females exhibited 
3.2- or more than a 200-fold increase in human engraftment in comparison with male 
recipients when 5x10
4
 or 5x10
3
 CB-CD34
+
 cells were transplanted, respectively. 
Additionally, there was no difference in the percentage of myeloid, B, T cells or HSPCs 
(hCD34
+
, hCD34
+
hCD38
-
 and hCD34
+
hCD38
-
hCD90
+
) within the human engraftment 
(supplemental Figure 1). These data pointed out the importance of the gender of the NSG 
mouse recipients to facilitate the engraftment of human HSPCs.  
 
Human HSPC subsets expressed both ESR1 and ESR2  
To understand the potential role of sex hormones in the observed differences of human 
hematopoietic engraftment between male and female recipient mice, we analyzed the 
expression of the two main estrogen receptors, ESR1 and ESR2, in CB-CD34
+
 cells. As 
shown in the immunostaining analysis of Figure 2A and 2B, most CD34
+
 cells were positive 
for ESR1 staining, while ESR2 staining was dimmer in CD34
+
 cells (Figure 2A-B; 
supplemental Figure 2A). Additionally, to investigate the differential expression of these 
receptors in the hematopoietic progenitors, different populations of HSPCs, such as 
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HSC/MPP (CD34
+
CD38
-
CD45RA
-
), Multilymphoid Progenitors (MLP, CD34
+
CD38
-
CD45RA
+
) 
and committed hematopoietic progenitors (Hem Prog, CD34
+
CD38
+
), were sorted out 
(supplemental Figure 2B) and the expression of both estrogen receptors was determined 
by qRT-PCR. Both ESR1 and ESR2 were expressed in HSCs, MLPs and in more committed 
hematopoietic progenitors (Figure 2C-D; supplemental Figure 2C). ESR1 expression tends 
to be up-regulated between HSC/MPP and MLP compartments to again fall down in the 
most committed hematopoietic progenitors (Figure 2C). On the contrary, ESR2 expression 
seems to follow an opposite pattern with high values in both HSC/MPP and committed 
hematopoietic progenitors but reduced levels in the MLP cell population (Figure 2D). In 
both cases, although some tendencies could be observed, no statistical significance was 
observed. On the other hand, the new identified estrogen receptor, GPER1, as in the case 
of ESR1 and ESR2, was also detected in CB-CD34
+
 from different donors by RT-PCR 
(supplementary Figure 2D). Consequently, human HSPCs might respond to natural 
estrogens through any of the estrogen receptors. 
 
Natural estrogens modified human HSPCs in vitro  
Once demonstrated that both estrogen receptors were expressed in HSPCs, we wanted to 
investigate a potential direct effect of estrogens on human HSPCs. We cultured CB-CD34
+
 
for four days with a range of concentrations, from 10nM to 500µM, of the four natural 
estrogens (E1, E2, E3 and E4). As shown in Figure 3A, E1 and E3 reduced the expansion of 
the cells in culture practically at any used concentration. On the other hand, the lowest 
concentrations of E2 or E4 promoted the expansion of these cells, but they impaired the 
cell growth at high doses. A similar behavior was detected when different subpopulations 
of hCD34
+
 cells were analyzed (Figure 3B and supplemental Figure 3A-E). E1 prevented the 
expansion of hCD34
+
hCD38
- 
cells (supplemental Figure 3C), MLPs (supplemental Figure 
3D), Multipotent Progenitors (MPPs, hCD34
+
hCD38
-
hCD90
-
hCD45RA
-
, supplemental Figure 
3E) and most primitive HSCs (hCD34
+
hCD38
-
hCD90
+
hCD45RA
-
, Figure 3B). The data from 
the rest of tested estrogens showed an apparent amplification of these primitive 
populations at low concentrations, but they were toxic at the highest concentrations 
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(Figure 3B; supplemental Figure 3C-E). It is important to highlight that the best tolerated 
estrogen was E4. Concentrations up to 10μM of E4 seemed not to be detrimental to any 
of these HSPC subsets, including primitive HSCs. On the contrary, E2 induced apoptosis in 
HSPCs at high doses (supplemental Figure 3F-G), as previously described for this estrogen 
and tamoxifen
24, 27
. However, only human HSPCs cultured in presence of the highest 
concentration of E4 showed some induction of apoptosis. Furthermore, we analyzed the 
cell cycle of CB-CD34
+ 
cells after 4-day culture in presence of 100nM E2 or E4. Estrogens, 
mainly E4, induced an increment of cells in G2/M phase (Figure 3C and supplemental 
Figure 3H), which might explain the tendency of these two estrogens to expand human 
hematopoietic progenitors.  
 
Previously, E2 was described to have a positive role in enhancing both CB-CD34
+
 
proliferation and in vitro hematopoietic progenitor potential after more than week in vitro 
treatment
28
. Hence, we cultured human HSPCs in presence of the lowest and best 
tolerated doses of E2 or E4 for eight days. We could detect a significant expansion of 
human progenitors with E4 with all the tested concentrations (Figure 3D). In addition, a 
similar effect was identified with 100nM E2. Furthermore, the better tolerance of E4 over 
E2 was also confirmed, since all the tested concentrations of E4 were non-toxic for CB-
CD34
+
 cells (Figure 3D). Additionally, the in vitro functionality of the estrogen-treated 
HSPCs was assessed with Colony Forming Unit (CFU) assays. We did not observe any 
differences among the groups in CFU numbers or CFU types (supplemental Figure 3I).  
 
In order to assess which estrogen receptor was involved in the role of these molecules in 
human HSPCs, cell cycle of CB-CD34
+
 was determined in presence of these two estrogens 
together with either ESR1 antagonist (MPP), ESR2 antagonist (PHTPP) or GPER1 antagonist 
(G-15). The treatment with E2 or E4 alone tended to increase the percentage of cells in 
S/G2/M-phase as previously described; however, the addition of ESR2 antagonist seemed 
to block the increase of cells in S/G2/M-phase induced by E4 (Supplemental Figure 3J); 
less clearly, ESR1 and GPER1 antagonists seemed to reduce the number of cells in 
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S/G2/M-phase in E2-treated HSPCs. Moreover, expression of ESR1 and ESR2 were 
assessed in human HSPCs cultured with estrogens for four days by immunofluorescence 
analysis (supplemental Figure 3K-L). While ESR1 fluorescence intensity increased slightly 
but significantly with 100nM of E2 or E4 (supplemental Figure 3K and supplemental Figure 
3M), ESR2 expression was significantly increased in presence of both E2 and E4 
(supplemental Figure 3L and supplemental Figure 3N). Moreover, estrogen treatment 
extended the percentage of human HSPCs showing a polarized localization of ESR1 at the 
membrane (supplemental Figure 3K and supplemental Figure 3O). Furthermore, the 
treatment with estrogens enhanced the percentage of human CD34
+
 with cytoplasmic 
localization of ESR2 (supplemental Figure 3L and supplemental Figure 3P).  
 
Altogether, the data indicate natural estrogens regulate human HSPCs through the 
signaling of estrogen receptors.  
 
E2 and E4 increased the number of human HSPCs in an in vitro model of human 
hematopoietic niche 
Subsequently, we investigated the indirect effect of E2 and E4 on HSPCs in an in vitro 
model of human hematopoietic niche. CB-CD34
+
 cells were co-cultured on an irradiated 
human BM-MSC layer in the presence of 100nM or 1μM of E2 and E4 (supplemental 
Figure 4A). We analyzed the expansion of the hematopoietic cells in two ways: i) after a 
week of co-culture (Figure 4), or ii) after four weeks of co-culture with the estrogen 
present only during the first week (supplemental Figure 4C-D). From 10nM to 1μM E4 and 
the lowest concentration of E2 increased the hematopoietic cells in the culture in the first 
week of co-culture (Figure 4A). Likewise, the number of hCD34
+
 cells in the co-culture was 
significantly higher in E4 and 10nM E2 treated conditions than in the control group (Figure 
4B; supplemental Figure 4B). However, we could not detect significant differences in the 
functionality of those hCD34
+
 cells in CFU assays (Figure 4C). Additionally, the effect of 
these two estrogens on the expansion of human hematopoietic cells or hCD34
+
 cells 
seemed not to be enhanced after four weeks in co-culture with an initial single dose 
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(supplemental Figure 4C-D). Consequently, the positive effect of E2 and E4 on HSPCs also 
occurs in an in vitro model of human hematopoietic niche. 
 
E2 and E4 boosted human hematopoietic engraftment in immunodeficient mice  
To better evaluate the impact of E2 and E4 on the properties of HSPCs, we transplanted 
5x10
4
 human CB-CD34
+
 cells into sub-lethally irradiated male NSG mice, in order to avoid 
any additional effects of endogenous estrogens of female recipient mice, and three days 
later the animals were treated with vehicle or with daily low doses of either E2 or E4 (2μg 
of estrogen per day) for four days (Figure 5A). Human hematopoietic engraftment was 
evaluated in the mouse BM by FACS analysis four month post-transplant (mpt, 
supplemental Figure 5A). Surprisingly, the human hematopoietic contribution was 
significantly higher in the estrogen-treated animals than in vehicle-treated ones (Figure 
5B; supplemental Figure 5A). Additionally, none of the estrogens altered the normal 
distribution of human hematopoietic lineages within the hCD45
+
 population 
(supplemental Figure 5B-5D). More importantly, E4 administration significantly enhanced 
human CD34
+
 population in male NSG mice (Figure 5C). No increase in the presence of the 
more primitive compartment, hCD34
+
hCD38
-
, was observed (Figure 5D). To explore the 
impact of the estrogen treatment in the long-term HSC (LT-HSC), secondary transplants 
were performed. One million hCD45
+ 
cells, purified from the bone marrow of the primary 
recipients, were transplanted into sub-lethally irradiated female NSG mice. As shown in 
Figure 5E, the estrogen-treated human hematopoietic cells maintained their long-term 
engraftment potential without any observable problem in the human hematopoietic 
reconstitution or any abnormal proliferation. This led us to conclude that these two 
estrogens, mainly E4, enhance in vivo human hematopoietic engraftment in male 
immunodeficient mice. 
 
To study this finding more in-depth, we transplanted limited numbers of human HSPCs 
(5x10
3
 CB-CD34
+
 cells/mouse), into male NSG mice, which were treated subsequently with 
vehicle, E2 or E4 as previously described. The percentage of mice positive for human 
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engraftment, defined as percentage of hCD45
+ 
cells greater than 0.1% of the cells in the 
mouse BM 4mpt, tended to increase after estrogen treatment (supplemental Figure 5E). 
Even more, the human hematopoietic chimerism of the positive animals seemed to be 
higher in the group treated with E4 than in the vehicle group (supplemental Figure 5F). So, 
E2 and E4 might be able to improve the engraftment of human HSPCs even when a very 
limited number of cells were transplanted. 
 
To explore if the engraftment enhancement mediated by estrogens occurred in female 
recipients as well, we repeated the transplant of this very low number of CB-CD34
+
 into 
sub-lethally irradiated female NSG nice. As shown in supplemental Figure 5G, human 
engraftment 4mpt tended to increase in the female animals treated with either of the two 
estrogens, although there was no significant difference among the groups. The percentage 
of hematopoietic progenitors within the human population did not show larger 
differences between vehicle- and estrogen-treated animals (supplemental Figure 5H). 
Consequently, there is no clear effect of E2 or E4 in the engraftment of human HSPCs into 
female animals. 
 
E4 impacts on MSCs within the mouse hematopoietic niche  
To provide a further insight into the positive impact of estrogens on promoting human 
hematopoietic engraftment, we assessed whether estrogens act in vivo on human HSPCs 
to promote hematopoietic engraftment directly or indirectly through niche cells. Thus, 
5x10
4
 CB-CD34
+
 cells were cultured with 100nM of E2 or E4 for 4 days and the resulting 
cells after the culture were transplanted in NGS mice. As it is shown in Figure 6A, human 
engraftment of in vitro estrogen-treated HSPCs was lower than vehicle-treated cells, 
which might indicate an indirect mechanism of estrogens to enhance hematopoietic 
engraftment in NSG mice. Additionally, there was no difference in the percentage of 
lymphoid, myeloid or HSPC subpopulations among mice in the different groups 
(supplemental Figure 6A). To understand in depth the difference in engraftment between 
in vitro estrogen-treated HSPCs and in vivo effect of estrogens after HSCT, 5x10
4
 CB-CD34
+
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cells were co-cultured with human irradiated BM-MSCs in presence of 100nM of E2 or E4 
for a week, then the resulting cells were transplanted into sublethally irradiated NSG mice. 
Human engraftment and lineage distribution were similar among mice of the different 
groups (Figure 6B, supplemental Figure 6B), which indicated the loss of engraftment 
ability due to the in vitro estrogen-mediated expansion which might be offset by the BM-
MSCs. Next, we examined the contribution of the hematopoietic niche to the engraftment 
of human HSPCs after in vivo estrogen-treatment. Therefore, we analyzed the 
mesenchymal and vascular endothelial compartments of the mouse BM niche four 
months after being transplanted and treated with E2 or E4. The percentage of mouse 
MSCs (mCD140a
+
, also called Pdgfra
+
) and vascular endothelial cells (mCD144
+
, also called 
VE-Cadherin
+
) was analyzed in the non-hematopoietic compartment (supplemental Figure 
6C). Surprisingly, compartment of mCD140a
+
 cells, but not mCD144
+
 cells, was increased 
in the mice treated with E4 in comparison with vehicle-treated animals (Figure 6C-D). To 
deepen on this point, mice were sublethally irradiated and treated with estrogens without 
human HSPCs transplantation. Surprisingly, there were more nucleated cells in the BM of 
mice treated with E4 (supplementary Figure 6F). Those mouse BM cells were cultured to 
study their ability to form fibroblast colony-forming units (CFU-Fs). We identified a 
tendency to have more CFU-Fs in the BM from estrogen-treated mice than vehicle-treated 
mice (Figure 6E and supplemental Figure 6G), which might indicate the beneficial role of 
estrogens to ameliorate BM niche after irradiation.  
 
Then, we evaluated whether human mesenchymal stromal cells might interact with these 
estrogens. So, the expression of ESR1 and ESR2 was also analyzed in the human BM-MSCs 
compartment by RT-PCR (Figure 6F) and immunofluorescence (Figure 6G; supplemental 
Figure 6H). Both estrogen receptors were present in human BM-MSCs, indicating that the 
presence of estrogens could influence the behavior of these human stromal cells and 
affect indirectly the biology and/or the engraftment of humans HSPCs. To investigate the 
effect of estrogens on human BM-MSCs, a limiting number of human BM-MSCs were 
seeded and treated with estrogens and their CFU-F potential was assessed. As it is shown 
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in supplemental Figure 6I, the estrogens had no effect on human BM-MSC; nevertheless, 
CFU-F numbers dropped when those human BM-MSCs had been irradiated previously. 
However, we could observe an increase in the number of CFU-Fs when the BM-MSCs were 
treated with estrogens after irradiation (supplemental Figure 6I). Altogether, estrogens, 
and more importantly E4, might facilitate and favor the hematopoietic engraftment of 
human progenitors through enhancing mesenchymal compartment of the hematopoietic 
niche, in addition to its direct effect on HSPCs. 
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Discussion 
 
The present study describes the potential use of estrogens to modify human HSPCs 
engraftment in BM upon transplantation. On the basis of the differences in the level of 
human hematopoietic engraftment between female and male recipient mice (Figure 1 and 
supplemental Figure 1), and the expression of estrogen receptors in different subsets of 
human HSPCs (Figure 2 and supplemental Figure 2), we have explored the impact of 
estrogen treatment on hematopoietic cells engraftment. E2 and E4 showed a positive 
effect on the expansion of these cells in vitro by activating cell cycle (Figure 3 and 
supplemental Figure 3). Additionally, E4 was better tolerated than E2 (Figure 3 and 
supplemental Figure 3). Despite the modest role of these estrogens in modulating human 
progenitor activity in vitro, we found E2, and even more E4, able to boost human 
hematopoietic engraftment in immunodeficient mice (Figure 5 and supplemental Figure 
5). This better performance of human HSPCs in estrogen-treated animals might reflect the 
gender differences observed. Furthermore, an apparent expansion of the mouse 
mesenchymal stromal compartment was identified in the animals treated with E4, which 
may suggest an additional indirect regulation of the estrogens enhancing human 
hematopoietic engraftment through niche regulation (Figure 6 and supplemental Figure 
6). Thus, estrogens could act directly on HSPCs as well as indirectly, throughout the 
modification of the BM stroma, or BM niche, to enhance CD34
+
 cell engraftment. These 
results might be clinically relevant, since the use of E4 could facilitate HSPC 
transplantation when only a limited number of cells can be infused.  
 
We have shown that estrogens improve human engraftment in immunodeficient mice, 
which reinforces the role of sex hormones in HSPC regulation and might explain the 
superior performance of female mice as recipients of a hematopoietic transplant
26
 (Figure 
1). The importance of estrogens in regulating HSPC functions has been explored for a long 
time, without any clear conclusion. E3 has been found to trap mouse hematopoietic 
progenitors in the liver
29
. E2 has been described as promoting the cell proliferation of very 
primitive mouse HSCs. The increase of estrogen levels during pregnancy has also been 
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associated to a greater HSC division, higher HSC frequency and an increase in 
erythropoiesis
19, 27
. E2 has also been reported to expand human CB-CD34
+
 in vitro
28
.  
These data contrasts with those described by Illing et al in mice, previously, where a long-
term treatment with E2 stimulated mouse HSPCs in the vascular but not in the endosteal 
niche, impairing long term reconstitution potential
18
. On the other hand, high doses of E2 
suppressed hematopoiesis in mouse bone marrow
30
. This negative effect caused by 
estrogens has also been pointed out in tamoxifen treatment, which increased mouse HSC 
proliferation, but not self-renewal, and induced apoptosis in ST-HSCs and MPPs
24
. Here, 
we describe human HSPCs as having different sensitivities to any of the four natural 
estrogens. E1, and to a lesser extent E3 and E2 were toxic for human HSPCs (Figure 3; 
supplemental Figure 3). In contrast, E4 was better tolerated and was able to promote 
some degree of expansion of the human HSPCs by activating their cell cycle and a lower 
induction of apoptosis (Figures 3-4; supplemental Figure 3-4). These observations might 
explain the apparently divergent effects described previously for the different estrogens 
investigated, since different doses and different estrogens have been used in the above-
mentioned reports.  
 
Additionally, we observed that E2 or E4 treatment in vivo enhanced human hematopoietic 
engraftment in male mice transplanted with 5x10
4
 human HSPCs (Figure 5B and 
supplemental Figure 5), but only to a minor degree in animals transplanted with very 
limited number of CB-CD34
+
 (supplemental Figure 5E-G). The apparent lack of 
effectiveness in female mice might be due to the presence of endogenous estrogens in 
these female animals. Future experiments should be done with ovariectomized mice or 
taking the estrous cycle of female recipients into account to identify the real effect on 
HSPCs in female recipients. Furthermore, E4 treatment enlarged hCD34
+
 population in the 
already boosted human hematopoietic engraftment, but its impact on the hCD34
+
hCD38
-
 
and on secondary transplant was lower (Figure 5D-E). Nevertheless, although the 
percentage of hCD34
+
hCD38
- 
population was unmodified by the estrogen treatment, the 
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total cell number of this primitive population was enlarged since the human engraftment 
was higher in estrogen-treated mice (Figure 5B and 5D).  
 
We have described a positive effect on human engraftment after E2 or E4 treatment, 
being the impact of E4 the most significant. It is important to note that E4 is synthesized 
exclusively by the human liver during pregnancy. It is detected at 9 weeks of pregnancy, 
reaches high levels in the second trimester, with steadily rising concentrations of E4 
toward the end of pregnancy
31
. On the other hand, fetal liver is a hematopoietic organ 
during the last half of the gestation period. During the hematopoietic stage of the fetal 
liver, different signaling pathways are coordinated to promote both a massive expansion 
of HSCs through the activation of the HSC cell cycle and a massive production of erythroid 
cells. After birth, the HSCs migrate from the liver to the adult bone marrow, where the 
most primitive HSCs are largely quiescent
1, 32
. The concurrence of E4 synthesis in the fetal 
liver, when it is a hematopoietic organ, may suggest an indirect link between this estrogen 
and the expansion of human HSPCs during pregnancy. The association between estrogens 
and hematopoietic development has previously been described during zebrafish 
development
33
, in mouse
19, 27
 and in the hematopoietic differentiation of human iPSCs
28
. 
So estrogens have a clear impact on HSC emergence. Similarly, Oguro et at. demonstrated 
the coordination between E2 and 27-hydroxycholesterol to regulate hematopoiesis during 
pregnancy
27
. Consequently, we can hypothesize a likely role of E4 in modulating early 
human hematopoiesis during embryo development.  
 
All previously reported observations could be attributed to an intricate regulation 
mediated by the estrogens
17
. The complexity of the estrogen signaling pathways starts 
with the existence of several estrogen receptors. Three of these receptors (ESR1, ESR2 and 
GPER
34
) are expressed in hematopoietic cells, but only ESR1 has been described to play a 
role in the regulation of HSCs
18, 19, 24
. A second level of complexity is that the expression of 
these estrogen receptors tends to differ among hematopoietic subpopulations
24
 (Figure 
2). Moreover, different estrogens vary in their binding affinity to different estrogen 
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receptors; for example, E2 shows 7 times higher affinity for ESR1 (inhibition constant, 
Ki=0.21nM) than for ESR2 (Ki=0.015nM), and E4 has 400 times higher affinity for ESR1 
(Ki=4.9nM) than ESR2 (Ki=19nM)
35
. Even more, once the estrogen and receptor are bound, 
specific cell responses will be triggered by two different mechanisms: i) gene expression 
programs can be initiated through the estrogen nuclear signaling, or ii) the estrogens can 
act through membrane-initiated steroid signaling (MISS), which is a rapid extra-nuclear 
cellular response to the estrogen signal
15
. These two types of estrogen signaling also can 
explain the differences we have observed between E4 and E2, from their toxicity and 
expansion in vitro (Figure 3; supplemental Figure 3) to their in vivo effect (Figures 6). E4 
uncouples the nuclear activation and MISS in contrast to E2 which does not
15
. For 
example, E4 works as an estrogen antagonist on breast cancer cells
31, 36
. Moreover, the 
lower affinity of E4 to estrogen receptors in comparison with E2 might suggest a very 
limited effect of E4 on HSPCs; however, E4 doses, whose effects on HSPCs were observed 
(Figures 3-4), were the same doses used by Abbot et al. in which ERE transcriptional 
activity could be detected
15
. What’s more, since E4 lacks of MISS activity, it is likely that 
the impact of E2 and E4 on human HSPCs might be due to their nuclear signaling, with 
similar transcriptional output, but this point will have to be analyzed in depth. 
Additionally, the presence of E2 or E4 increased the levels of both ESR1 and ESR2 and their 
cellular localization. Furthermore, the increment of cells in S/G2/M-phase mediated by 
estrogens could be partially blocked by ESR1 and GPER antagonist in the case of E2, and by 
ESR2 antagonist in the case of E4 (supplemental Figure 3J). Consequently, different 
estrogen receptors in human HSPCs might be involved in the signaling triggered by E2 or 
E4; however, this point will require more in-depth study. More interestingly, E2 might 
activate estrogen receptor-mediated MISS, since a clear polarized location of the estrogen 
receptors in the cytoplasm membrane was found (supplemental Figure 30-P). On the 
other hand, E4 might activate nuclear estrogen signaling, since E4 is unable to induce 
MISS
15
 and a clear increment of ESR2 in the cytoplasm was detected (supplemental Figure 
3N). The consequences of ESR1 and ESR2 upregulation and localization should be explored 
in future experiments. Additionally, Oguro et al. 
27
 described two different ESR1 ligands, 
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such as E2 and 27-Hydroxycholesterol, which regulated HSPCs differentially during 
pregnancy. Both ESR1 ligands collaborated to induce HSC proliferation, mobilization and 
extramedullary hematopoiesis. In a similar way, E2 and E4 might collaborate together to 
impact differentially on human HSPCs. 
 
We identified that the underlying mechanism mediated by estrogens is through the 
activation of cell cycle in vitro, as previously described, which promote the expansion of 
hematopoietic progenitors
19, 24
. However, estrogens might also cause different effects, 
such as the activation of telomerase activity to facilitate the expansion of HSPCs
20-22
, or 
increase of unfolded protein response (UPR) to promote hematopoietic regeneration after 
a proteotoxic stress, such as irradiation
23, 37
. In our in vivo model, E2 or E4 might activate 
the gene signaling involved in the cell cycle
19, 24
, telomerase
20-22
 or UPR
23
; but these 
estrogens could also activate apoptosis
24, 27
 when high doses are used (Figure 3 and 
supplemental Figure 3G-H). Surprisingly, this estrogen-mediated expansion observed in 
vitro was not enough to explain the improvement in human hematopoietic engraftment. 
Indeed, the in vitro proliferation of human HSPCs induced by the estrogens was 
counterproductive to the enhancement of hematopoietic engraftment (Figure 6A). This 
might be due to the reduction of long-term engraftment ability of cycling HSPCs 
2, 38
, and 
the decoupling of HSPC expansion and stem cell properties in vitro
39
. As HSC quiescence, 
self-renewal and differentiation is controlled through intrinsic HSC signaling and extrinsic 
niche signaling, we could observe that the co-culture of HSPCs with human BM-MSCs was 
able to expand hematopoietic cells (Figure 4) and maintain engraftment potential (Figure 
6B), which indicates that in vitro expansion of HSPCs might be compensated by niche 
signaling. In accordance with this, estrogens could also modulate hematopoiesis by 
affecting MSC capacity to promote osteogenesis
30, 40
. Furthermore, this osteogenic 
differentiation might favor the proliferation of HSPCs
25
. The beneficial effect of E2 to 
expand both HSPCs and MSCs has been seen by Kitajima et al. previously
41
. As shown in 
Figure 6, an increase in MSCs was also detected in our in vivo model after E4 treatment. 
Besides, estrogen presence might favor the recovery of MSCs after irradiation (Figure 6E 
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and supplemental Figure 6E-G), as previously published for HSPCs
23, 37
. Consequently, the 
impact of estrogens on promoting human hematopoietic engraftment in immunodeficient 
mice might be mediated through the regeneration of the mesenchymal stromal cell 
compartment of the BM niche after irradiation, or a combined effect on human HSPCs 
(Figure 2-3) and niche cells (Figure 6). Consequently, we can hypothesize estrogens might 
coordinate HSPC proliferation and recovery of BM niche in a HSCT context 
 
Based on the reported results, some significant clinical implications could be suggested. E4 
has a safer therapeutic window than E2, which facilitates its clinical use
31
. Additionally, 
there are several clinical trials where E4 has been tested and its safety and efficacy have 
been assessed for different conditions, such as contraception
42
, menopause
43
, 
osteoporosis
44
 or breast cancer
45
. Therefore, the clinical application of E4 to modulate 
HSPCs would be considered for improving HSPC transplantation in the near future. The 
potential clinical use of E4 might facilitate the transplantation of single CB units, the 
autologous transplant of gene therapy corrected HSPCs to treat inherited hematopoietic 
diseases or in any situation in which a reduced amount of HSPCs needs to be infused. The 
administration of a clinically approved estrogen, such as E4, after HSPCT could lead to an 
improvement in the overall hematopoietic engraftment of the transplanted patients.   
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Figure Legends  
 
Figure 1.  
Human Hematopoietic Stem Progenitor Cells show a superior hematopoietic 
engraftment in female than in male NSG mice. (A) Representative flow cytometry 
analyses of human engraftment of 5x10
4
 umbilical cord blood CD34
+
 (CB-CD34
+
) cells into 
sub-lethally irradiated female (left panel) and male (right panel) NOD.Cg-
Prkdc
scid
 Il2rg
tm1Wjl
/SzJ (NSG) mice 4 months post transplantation. (B) Percentage of human 
hematopoietic cells, hCD45
+
, in the bone marrow of female (F) or male (M) animals 
transplanted with 5x10
3
 or 5x10
4
 CB-CD34
+
cells. Data are obtained from 6 independent 
biological replicates. Data are presented by dots and box-plots that represent the 
interquartile range (p75, upper edge; p25, lower edge; p50, midline; p95, line above the 
box; and p5, line below the box). Significance was analyzed by Mann–Whitney U test and 
represented by **P <0.01 and ****P<0.001. 
 
Figure 2.  
Human Hematopoietic Stem Progenitor Cells express estrogen receptors. (A) 
Representative immunofluorescent image of umbilical cord blood CD34
+
 (CB-CD34
+
)  cells 
stained with anti-ESR1 (green), anti-hCD34 (red) and DAPI (blue). Insert, showing ESR1
+
 
CD34
+
 cells (marked with arrows), is an enlargement of the white boxed area. (B) 
Representative immunofluorescent image of CB-CD34
+
 cells stained with anti-ESR2 
(green), anti-hCD34 (red) and DAPI (blue). Insert, showing ESR2
+
 CD34
+
 cells (marked with 
arrows), is an enlargement of the white boxed area. (C) qRT-PCR analysis of ESR1 
expression of sorted Hematopoietic Stem Cell/Multipotent Progenitors (HSC/MPPs, 
hCD34
+
hCD38
-
hCD45RA
-
), Multilymphoid Progenitors (MLPs, hCD34
+
hCD38
-
hCD45RA
+
) 
and committed Hematopoietic Progenitors (hCD34
+
hCD38
+
). (D) qRT-PCR analysis of ESR2 
expression of sorted HSC/MPPs, MLPs and Hematopoietic Progenitors (hCD34
+
hCD38
+
). 
Data are obtained from 3 biological replicates. Data are presented by mean±SD. 
Significance was analyzed by one-way Anova with Fisher’s LSD test, no significant 
differences were found. 
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Figure 3.  
Natural estrogens affect human Hematopoietic Stem Progenitor Cells differently. (A) 
Total cell number of the estrogen-treated Hematopoietic Stem Progenitor Cells (HSPCs) 
after 4 days in culture.  Different concentrations (10nM, 100nM, 1μM, 10μM, 100μM and 
500μM) of the natural estrogens (E1, E2, E3 and E4) were used. (B) Total number of the 
Hematopoietic Stem Cell (HSCs, hCD34
+
hCD38
-
hCD90
+
hCD45RA
-
) after 4 days in culture. 
Different concentrations (10nM, 100nM, 1μM, 10μM, 100μM and 500μM) of the natural 
estrogens (E1, E2, E3 and E4) were used. (C) Cell cycle analysis of HSPCs treated with 
100nM E2 or E4. G0/G1-phase (left panel), S-phase (middle panel) and G2/M-phase (right 
panel). (D) Total cell number of the estrogen-treated HSPCs after 8 days in culture. Data 
are obtained from 3-5 biological replicates. Data are presented by mean±SD. Significance 
was analyzed by one-way Anova with Fisher’s LSD test and represented by *P<0.05 and 
**P <0.01. 
 
Figure 4.  
E2 and E4 impact on Hematopoietic Stem Progenitor Cells in an in vitro model of human 
hematopoietic niche. (A) Total hematopoietic cells after 1 week of co-culture with human 
bone marrow mesenchymal stromal cells (BM-MSCs) in presence of estrogens.  (B) Total 
hCD34
+
cells after 1 week of co-culture with human BM-MSCs in presence of estrogens. (C) 
CFUs derived from Hematopoietic Stem Progenitor Cells (HSPCs)  after 1 week of co-
culture with human BM-MSCs in presence of estrogens. Data are obtained from 3-6 
biological replicates. Data are presented by mean±SD. Significance was analyzed by one-
way Anova with Fisher’s LSD test and represented by *P<0.05 and **P <0.01. 
 
Figure 5.  
E2 and E4 enhance human engraftment in immunodeficient male mice. (A) Experimental 
scheme of human Hematopoietic Stem Progenitor Cells (HSPCs) into immunodeficient 
mice. Sub-lethally irradiated NOD.Cg-Prkdc
scid
 Il2rg
tm1Wjl
/SzJ (NSG) mice were transplanted 
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with human umbilical cord blood CD34
+
 (CB-CD34
+
) cells, and three days later the animals 
were treated with vehicle or with daily low doses of either E2 or E4 (2μg of estrogen per 
day) for four days. Four mpt the human hematopoietic engraftment was evaluated in the 
mouse bone marrow.  (B) Percentage of hCD45
+
 cells in the bone marrow (BM) of male 
mice transplanted with 5x10
4
 hCB-CD34
+
 cells 4 months post transplantation.  (C) 
Percentage of hCD34
+
 within the human population in the BM of male mice transplanted 
with 5x10
4
 hCB-CD34
+
 cells 4 months post transplantation. (D) Percentage of 
hCD34
+
hCD38
-
 within the human population in the BM of the transplanted male mice with 
5x10
4
 hCB-CD34
+
 cells. (E) Percentage of human engraftment (hCD45
+
) in the BM of 
secondary NSG mice transplanted with 1x10
6
 sorted hCD45
+
 cells from the primary 
recipients and analyzed 4 months post transplantation. Data were obtained from 4 
biological replicates. Data are presented by dots and box-plots that represent the 
interquartile range (p75, upper edge; p25, lower edge; p50, midline; p95, line above the 
box; and p5, line below the box). Significance was analyzed by Mann–Whitney U test and 
represented by **P <0.01 and ****P<0.001. 
 
Figure 6.  
Estrogens modulate hematopoietic niche. (A) Human engraftment in bone marrow (BM)  
of male mice transplanted with the expanded cells from initial 5x10
4
 hCB-CD34
+
 cells after 
4 days in culture in presence of 100nM of E2 or E4. The human engraftment was analyzed 
2 months post transplantation. (B) Human engraftment of in BM of male mice 
transplanted with the expanded cells from initial 5x10
4
 hCB-CD34
+
 cells after 1 week in co-
culture with irradiated human BM-MSCs in presence of 100nM of E2 or E4. The human 
engraftment was analyzed 3 months post transplantation. (C) Relative percentage of 
mouse mesenchymal stromal cells (MSCs, mCD45
-
Ter119
-
hCD45
-
hCD235a
-
mCD140a
+
) in 
the BM of male mice transplanted with 5x10
4
 hCB-CD34
+
 cells analyzed 4mpt. (D) Relative 
mouse vascular endothelial cells (mCD45
-
Ter119
-
hCD45
-
hCD235a
-
mCD144
+
) in the BM of 
the male mice transplanted with 5x10
4
 hCB-CD34
+
 cells analyzed 4mpt. (E) Number of 
fibroblast colony-forming units (CFU-Fs) derived from BM of vehicle- or estrogen-treated 
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mice after sublethal irradiation. (F) Representative agarose gel showing the PCR products 
of RT-PCR analysis of ESR1 (top panel), ESR2 (middle panel) and HPRT1 (bottom panel) in 
human BM-MSCs. (G) Representative immunofluorescence image of human BM-MSCs 
stained with anti-ESR1 (green, left panel), anti-ESR2 (green, middle panel) or secondary 
antibody (green, right panel) and DAPI (blue). Data were obtained from 3 biological 
replicates. Data are presented by dots and box-plots that represent the interquartile range 
(p75, upper edge; p25, lower edge; p50, midline; p95, line above the box; and p5, line 
below the box). Significance was analyzed by Mann–Whitney U test and represented by 
**P <0.01. 
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SUPPLEMENTAL METHODS 
 
RT and qRT-PCR analysis 
mRNA from whole or sorted subpopulations of CB-CD34+ cells and human BM MSCs was 
purified by TRIzolTM reagent (ThermoFisher) protocol and retro-transcribed by 
SuperScript™ VILO™ cDNA Synthesis Kit (ThermoFisher) to obtain cDNAs. qRT-PCR was 
carried out using Fast SYBR Green Master Mix (ThermoFisher). The specific primers to 
analyses: ESR1 were as Forward (ATCCACCTGATGGCCAAG) and as Reverse 
(GCTCCATGCCTTTGTTACTCA), ESR2 were as Forward (GATGCTTTGGTTTGGGTGAT) and as 
Reverse (AGTGTTTGAGAGGCCTTTTCTG) and HPRT1 were as Forward 
(ATGATGGGGCTGATGTGG) and as Reverse (TTCTACGCATTTCCCCTCA). The relative 
expression of each estrogen receptor to HPRT1 was calculated according Pfaffl’s method1. 
Additionally, the specific size of the PCR products was verified in 2% agarose gel. GPER1 
expression was analyzed through RT-PCR using specific primers, as Forward 
(AAAACAAATTTGCCGGCCCT) and as Reverse (TGAACCTCACATCCGACTGC), and visualized 
in an agarose gel. 
 
Immunofluorescence analysis 
CB-CD34+ cells and human BM-MSCs were cultured in Retronectin-treated chambers for 
one day. Then, they were fixed with 4% PFA for 10 minutes, blocked and permeabilized for 
1 hour with PBS/1% BSA/10% FBS/0.3M Glycine/0.1% Tween20. Finally, the cells were 
stained by either rabbit anti-ESR1 (Abcam) or anti-ESR2 (Abcam) together with mouse 
anti-hCD34-PE (Becton Dickinson Pharmingen, BD) and then washed and stained by a 
secondary anti Rabbit-Alexa488 (Molecular Probes) and counterstained by 4’,6-Diamidino-
2-phenylindole (DAPI; Roche) to visualize cell nuclei. All the images were visualized in 
Axioplan 2 imaging (Zeiss) fluorescent microscope. 
 
ESR1 and ESR2 fluorescence intensity and cellular localization were analyzed in 
immunofluorescence images acquired with the same exposure settings of CB-CD34+ cells 
cultured for 4 days with CTL, 100nM E2, 1µM E2, 100nM E4 or 1µM E4. From 20 to 55 
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different HSPCs were analyzed per condition to calculate fluorescence intensity and 
cellular localization: 1) cells with a reduced cellular presence of ESR1 or ESR2, 2) cells with 
polarized localization of ESR1 or ESR2 at the membrane, 3) cells with a localization of ESR1 
or ESR2 at the membrane and 4) cells with a cytoplasmic localization of ESR1 or ESR2.   
Immofluorescence analysis was performed with ImageJ 1.45 software (National Institutes 
of Health). 
 
Estrogens 
E1, E2, E3 and E4 (Sigma-Aldrich) were dissolved in ethanol for in vitro experiments or in 
olive oil for in vivo administration. Estrogen receptors antagonists, such as MPP (ESR1 
antagonist), PHTPP (ESR2 antagonist) or G-15 (GPER1 antagonist), all of them from Tocris, 
were suspended in DMSO. 
 
Human CB-CD34+ culture 
Purified CB-CD34+ cells were cultured in serum-free X-Vivo 20 media (BioScience-Lonza) 
without phenol red and supplemented with 100ng/mL rSCF (EuroBioSciences), 100ng/mL 
FLT3L (EuroBioSciences), 100ng/mL TPO (Bio-Techne) and 0.5% Penicillin-Streptomycin 
(Thermofisher) at 5x105 cells/mL. The indicated estrogens concentrations were added in 
each condition. Viable cells were determined with Trypan blue. The human hematopoietic 
phenotype was analyzed by flow cytometry (LSR Fortessa; BD). The cells were stained with 
hCD34-PECy7 (BioLegend), hCD45RA-FITC (Beckman Coulter), hCD38-PE and hCD90-APC 
(BD). DAPI-positive cells were excluded from the analysis. Analysis was performed using 
FlowJo software. Colony-forming Unit (CFU) assay was performed in HSC-CFU media 
(StemCell Technologies), and 14 days after, the number and type of hematopoietic CFUs 
were analyzed. In some experiments, 4-day cultured cells were transplanted into sub-
lethally irradiated NSG mice. 
 
For Cell Cycle analyses, HSPCs were fixed and permeabilized with BD Cytofix/Cytoperm kit 
(Thermofisher) and the DNA was stained with DAPI. Cell cycle analyses were done using 
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Moffitt software. To investigate the effect of the different estrogen receptors antagonist, 
CB-CD34+ cells were cultured as previously indicated adding MPP (1μM), PHTPP (1μM) or 
G-15 (3μM) for 4 days. Additionally, apoptosis of HSPCs was analyzed after 4 days in 
culture with different concentrations of E2 or E4, and the apoptotic cells were determined 
through flow cytometry with FITC Annexin V (BD Bioscience) and DAPI staining. 
 
Additionally, co-culture experiments were carried out by adding 5x104 CB-CD34+ cells on 
30Gy irradiated BM-MSC layer. The cells were maintained in no phenol red MEM alpha 
with 15% Horse serum, 15% HycloneTM Fetal Bovine Serum and 0.5% Penicillin-
Streptomycin (all from Thermofisher). Half of the media was refreshed every week. 
Different concentrations of estrogens were added at the beginning of the culture. After 1 
or 4 weeks, the culture was tripsinized and cell number, human hematopoietic phenotype 
and CFU assay were performed as previously described. In some experiments, cultured 
cells were transplanted into sub-lethally irradiated NSG mice. 
 
Fibroblast colony-forming unit assay 
Male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice sub-lethally irradiated with 1.5 Gy. Three 
days later, the animals were treated with vehicle (olive oil) or with daily doses of either E2 
or E4 (2µg of estrogen per day) intraperitoneally for four days. Two weeks after 
irradiation, mice were sacrificed and BM from long bones of these animals was collected. 
The long bones were flushed, cut in small pieces and crushed before being digested with 
250μg/mL LiberaseDL (Roche) / 200U/mL DNaseI in HBSS at 37°C for 20 minutes. BM-
MNCs were counted and 3x105 cells were seeded in Mesencult media (StemCell 
Technologies) for 1 month. The Colony-Forming Cells (CFCs) were stained with 
hematoxylin and quantified under a stereo microscope. 
 
Human CFCs were generated after seeding 1000 human BM-MSCs from different healthy 
donors. One day after, the human BM-MSCs were irradiated with 10Gy or 20Gy or non-
irradiated (0Gy) and cultured in no phenol red MEM alpha (Thermofisher) supplemented 
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with 5% platelet lysate (Cook medical), 1% penicillin/streptomycin (Thermofisher). After 
two weeks, CFCs were stained and quantified as previously mentioned. 
 
Statistical analysis 
Statistical significance was determined using 1-way Anova with Fisher’s LSD test, Fisher's 
exact test or nonparametric Mann–Whitney U test or with GraphPad Prism 7. The 
mean±SD or dots and box-plots, which represent the interquartile range (p75, upper edge; 
p25, lower edge; p50, midline; p95, line above the box; and p5, line below the box), are 
shown in each graph. Additionally, the significance was represented by P-values: *P<0.05, 
**P<0.01, ***P<0.005 and ****P<0.001.  
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SUPPLEMENTAL FIGURES 
 
 
Supplemental Figure 1.  
Human hematopoietic cell lineages distribution is maintained in engrafted female or 
male mice. (A) Percentage of myeloid cells (hCD33+) within human hematopoietic 
population engrafted in female (F) or male (M) NSG mice transplanted with 5x103 or 5x104 
CB-CD34+ cells. (B) Percentage of B-cells (hCD19+) within human hematopoietic 
population. (C) Percentage of T-cells (hCD3+) within human hematopoietic population. (D) 
Percentage of hematopoietic progenitors (hCD34+) within human hematopoietic 
population. (E) Percentage of primitive hematopoietic progenitors (hCD34+hCD38-) within 
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human hematopoietic population. (F) Percentage of HSCs (hCD34+hCD38-hCD90+) within 
human hematopoietic population. ND no detected. Data are obtained from 6 independent 
biological replicates. Data are presented by dots and box-plots that represent the 
interquartile range (p75, upper edge; p25, lower edge; p50, midline; p95, line above the 
box; and p5, line below the box). Significance was analyzed by Mann–Whitney U test, no 
significant differences were found. 
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Supplemental Figure 2.  
Human HSPCs express estrogen receptors. (A) Single channels of the immonufluorescent 
images shown in Figure 2A-B. CB-CD34+ cells were stained with anti-ESR1 (top row, green) 
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or anti-ESR2 (middle row, green) or only secondary antibody (bottom row, green), and 
anti-hCD34 (top and middle row, red) or with the specific IgG (bottom row, red), and DAPI 
(blue). (B) Representative cell sorting strategy to purify the different subsets of CB-CD34+ 
cells: HSC/MPPs (hCD34+hCD38-hCD45RA-), MLPs (hCD34+hCD38-hCD45RA+) and 
committed Hematopoietic Progenitors (hCD34+hCD38+). Pre-sorted cells and post-sorted 
HSC-MPP cells are shown at left and right panels respectively. (C) Representative agarose 
gel showing the PCR products of qRT-PCR analysis of the Figure 2C-D, ESR1 (left panel), 
ESR2 (middle panel) and HPRT1 (right panel). Human breast cancer line MCF7 was used as 
control. (D) Representative agarose gel showing the PCR products of RT-PCR analysis of 
GPER1 (left panel) and HPRT1 (right panel) of three different CB-CD34+ samples. 
Significance was analyzed by one-way Anova with Fisher’s LSD test.  Data are obtained 
from 3 biological replicates (A-B-C). 
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Supplemental Figure 3.  
Natural estrogens affect different human HSPCs. (A) Representative dot-plots showing 
the flow cytometry analysis of different HSPC subsets, such as hCD34+hCD38-, MLP 
(hCD34+hCD38-hCD90-hCD45RA+), MPP (hCD34+hCD38-hCD90-hCD45RA-) and HSC 
(hCD34+hCD38-hCD90+hCD45RA-). (B) Representative dot-plots showing cytometry 
analysis of E2-treated HSPCs for four days.  (C) Number of hCD34+hCD38- cells within of 
estrogen-treated HSPCs after 4 days in culture. Different concentrations (10nM, 100nM, 
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1µM, 10µM, 100µM and 500µM) of the natural estrogens (E1, E2, E3 and E4) were used. 
(D) Number of the MLPs within of estrogen-treated HSPCs after 4 days in culture. Different 
concentrations (10nM, 100nM, 1µM, 10µM, 100µM and 500µM) of the natural estrogens 
(E1, E2, E3 and E4) were used. (E) Number of the MPPs within of estrogen-treated HSPCs 
after 4 days in culture. Different concentrations (10nM, 100nM, 1µM, 10µM, 100µM and 
500µM) of the natural estrogens (E1, E2, E3 and E4) were used. (F) Representative dot-
plots showing Annexin V analysis of E2- and E4-treated HSPCs for four days. (G) 
Percentage of alive, early apoptotic and late apoptotic HSPCs after estrogen treatment for 
four days. Different concentrations (10nM, 100nM, 1µM, 10µM, 100µM and 500µM) of E2 
and E4 were used. (H) Representative histogram showing Cell Cycle analyses of control 
(CTL) or HSPC treated with 100nM E2 or E4 for 4 days in culture. (I) Colony-Forming Unit 
(CFU) analysis from HSPCs cultured for 8 days in presence or absence of E2 or E4 at 10nM, 
100nM or 1µM. (J) Cell cycle analysis of HSPCs culture with 100nM of E2 or E4 in presence 
of different antagonists of estrogen receptors, such as MPP (ESR1 antagonist, 1μM), 
PHTPP (ESR2 antagonist, 1μM) or G-15 (GPER1 antagonist, 3μM). Data are obtained from 
3-5 biological replicates. (K) Representative ESR1 immunofluorescent images of CB-CD34+ 
cells cultured for 4 days with CTL, 100nM E2, 1µM E2, 100nM E4 or 1µM E4. ESR1 (green, 
left panels), DAPI (blue, middle panels) and DAPI (blue). (L) Representative ESR2 
immunofluorescent images of CB-CD34+ cells cultured for 4 days with CTL, 100nM E2, 1µM 
E2, 100nM E4 or 1µM E4. ESR2 (green, left panels), DAPI (blue, middle panels) and DAPI 
(blue). (M) Analysis of ESR1 fluorescence intensity in CB-CD34+ cells cultured for 4 days 
with CTL, 100nM E2, 1µM E2, 100nM E4 or 1µM E4. (N) Analysis of ESR2 fluorescence 
intensity in CB-CD34+ cells cultured for 4 days with CTL, 100nM E2, 1µM E2, 100nM E4 or 
1µM E4. (O) Classification of CB-CD34+ cells cultured for 4 days with CTL, 100nM E2, 1µM 
E2, 100nM E4 or 1µM E4 according ESR1 expression and subcellular.  Several examples of 
human CD34+ with different ESR1 cellular localization are indicated as: 1. Low/negative 
ESR1 presence, 2. Polarized localization at the membrane, 3. Localization at the 
membrane and 4. Cytoplasmic localization.  (P) Classification of CB-CD34+ cells cultured for 
4 days with CTL, 100nM E2, 1µM E2, 100nM E4 or 1µM E4 according ESR2 expression and 
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subcellular.  Several examples of human CD34+ with different ESR2 cellular localization are 
indicated as: 1. Low/negative ESR2 presence, 2. Polarized localization at the membrane, 3. 
Localization at the membrane and 4. Cytoplasmic localization.  From 20 to 55 different 
HSPCs were analyzed.  Data are presented by mean±SD. Significance was analyzed by by 
one-way Anova with Fisher’s LSD test or Chi-square test and represented by *P <0.05, **P 
<0.01, ***P <0.005 and ****P <0.001. 
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Supplemental Figure 4.  
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Impact of either E2 or E4 impact on HSPCs co-cultured with human BM-MSCs. (A) 
Representative bright-field microscopy images of control HSPCs (left panel), E2-treated 
HSPCs (middle panel) and E4-treated HSPCs (right panel) co-cultured with human BM-
MSCs for 1 week. (B) Representative dot-plots of control HSPCs (left panel), E2-treated 
HSPCs (middle panel) and E4-treated HSPCs (right panel) co-cultured with human BM-
MSCs for 1 week. Samples were stained with hCD34-PECy7. (C) Total number of control 
and estrogen-treated HSPCs after 4 weeks of co-culture with human BM-MSCs. (D) 
Percentage of the hCD34+ population within HSPCs co-cultured with BM-MSCs for 4 
weeks. Data are obtained from 2-6 biological replicates. Data are presented by mean±SD. 
Significance was analyzed by by one-way Anova with Fisher’s LSD test. 
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Supplemental Figure 5.  
E2 and E4 enhance human engraftment in immunodeficient mice (A) Representative dot-
plots of the flow cytometry analysis of NSG male mice transplanted with 5x104 hCB-CD34+ 
cells 4mpt. Human engraftment, hCD45+ cells (far left panels), human myeloid cells 
(hCD33+) and human B-cells (hCD19+) in the human population (center-left panels), human 
T-cells (hCD3+) and human B-cells (hCD19+) in the human population (center-right panels) 
and HSPC subsets (hCD34+ and hCD34+hCD38-) in the human population (far right panels) 
of vehicle-(top row) or E2- (middle row) or E4-treated mice. (B) Percentage of hCD19+ cells 
within the human population in the BM of male mice transplanted with 5x104 hCB-CD34+ 
cells 4mpt. (C) Percentage of hCD33+ cells within the human population in the BM of male 
mice transplanted with 5x104 hCB-CD34+ cells 4mpt. (D) Percentage of hCD3+ cells within 
the human population in the BM of male mice transplanted with 5x104 hCB-CD34+ cells 
4mpt. (E) Percentage of engrafted male NSG mice (percentage of hCD45+ cells within 
mouse BM higher than 0.1%) and non-engrafted ones 4mpt after transplanting 5x103 hCB-
CD34+ cells. Significance was analyzed by Fisher´s exact test, no significant differences 
were found. (F) Percentage of hCD45+ cells in the BM of engrafted male mice transplanted 
with 5x103 hCB-CD34+ cells 4mpt. (G) Percentage of hCD45+ cells in the BM of female mice 
transplanted with 5x103 hCB-CD34+ cells 4mpt. (H) Percentage of hCD34+ cells within the 
human population in the BM of female mice transplanted with 5x103 hCB-CD34+ cells 
4mpt. Data are obtained from 3-4 biological replicates. Data are presented by dots and 
box-plots that represent the interquartile range (p75, upper edge; p25, lower edge; p50, 
midline; p95, line above the box; and p5, line below the box). Significance was analyzed by 
Mann–Whitney U test and represented by **P <0.01. 
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Supplemental Figure 6.  
Estrogens modulate hematopoietic the niche. (A)  Percentage of hCD19+ cells (left panel) 
hCD33+ (center panel) and hCD34+ cells (right panel) within the human population in BM 
of male mice transplanted with the expanded cells from initial 5x104 hCB-CD34+ cells after 
4 days in culture in presence of 100nM of E2 or E4. The human engraftment was analyzed 
2mpt. (B) Percentage of hCD19+ cells (left panel) hCD33+ (center panel) and hCD34+ cells 
(right panel) within the human population in BM of male mice transplanted with the 
expanded cells from initial 5x104 hCB-CD34+ cells after 1 week in co-culture with irradiated 
human BM-MSCs in presence of 100nM of E2 or E4. The human engraftment was analyzed 
3mpt. (C) Representative dot-plots of the flow cytometry analysis of mouse MSCs 
(mCD140a+) and mouse vascular endothelial cells (mCD144+) within the non-
hematopoietic population (hCD45-hCD235a-mCD45.1-mTer119-) in the BM of NSG male 
mice transplanted with 5x104 hCB-CD34+ cells 4mpt. (D) Percentage of mouse MSCs 
(mCD140a+) within the non-hematopoietic population (mCD45-Ter119-hCD45-hCD235a-) in 
the BM of male mice transplanted with 5x104 hCB-CD34+ cells 4mpt. (E) Percentage of 
mouse vascular endothelial cells (mCD144+) within the non-hematopoietic population 
(mCD45-Ter119-hCD45-hCD235a-) in the BM of male mice transplanted with 5x104 hCB-
CD34+ cells 4mpt. (F) Total number of BM-MNCs per limb of mice two weeks after being 
sublethally irradiated and treated with vehicle or estrogens. (G) Number of Colony-
Forming Cells (CFCs) per 3x105 mouse BM-MNCs seeded in mesenchymal media. (H) Single 
channels of the immonufluorescent images shown in Figure 6C. Human BM-MSCs cells 
were stained with anti-ESR1 (left panel, green) or anti-ESR2 (middle panel, green) or only 
secondary antibody (right panel, green) and DAPI (blue). (I) Number of CFCs derived from 
human BM-MSCs of three different healthy donors after being irradiated with 10Gy or 
20Gy or without irradiation, and treated with vehicle, E2 or E4.  Data are obtained from 3 
biological replicates. Data are presented by mean±SD  or dots and box-plots that 
represent the interquartile range (p75, upper edge; p25, lower edge; p50, midline; p95, 
line above the box; and p5, line below the box). Significance was analyzed by Mann–
Whitney U test or one-way Anova with Fisher’s LSD test and represented by *P <0.05. 
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